echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Lancet Sub-Journal: A cohort study of more than 69 million people confirms once again that elevated BMI is associated with severe COVID-19 adverse outcomes

    Lancet Sub-Journal: A cohort study of more than 69 million people confirms once again that elevated BMI is associated with severe COVID-19 adverse outcomes

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In the early stages of the COVID-19 pandemic, obesity was considered an important risk factor.


    In the early stages of the COVID-19 pandemic, obesity was considered an important risk factor.


    To date, almost all studies on this potential association have examined the outcome of hospitalized patients and compared the progress or death of obese and non-obese patients to the intensive care unit (ICU).


    Some studies have found that men, certain ethnic groups, patients with type 2 diabetes and other chronic diseases may be more likely to have adverse consequences from severe SARS-CoV-2 infection .


    In this prospective, community-based cohort study, the researchers used the QResearch database from the UK general practice to identify patient-level data, and extracted data from January 24, 2020 (the date when the infection was first recorded in the UK) to Data of patients 20 years and older registered in QResearch database during April 30, 2020, and available data of BMI.


    In this prospective, community-based cohort study, the researchers used the QResearch database from the UK general practice to identify patient-level data, and extracted data from January 24, 2020 (the date when the infection was first recorded in the UK) to Data of patients 20 years and older registered in QResearch database during April 30, 2020, and available data of BMI.


    Among 6910695 eligible individuals (mean BMI 26.


    Researchers found that there is a significant interaction between body mass index and age and race, which is more important for young people and blacks than whites.


    When the BMI exceeds 23 kg/m 2 , the risk of hospital admission and death due to COVID-19 increases linearly.


    Correlation between BMI and COVID-19-related hospitalizations (A), COVID-19-related ICU hospitalizations (B), and COVID-19 deaths (C) in the general population

    Correlation between BMI and COVID-19-related hospitalizations (A), COVID-19-related ICU hospitalizations (B), and COVID-19 deaths (C) in the general population

    Even a small increase in BMI above 23kg/m 2 is a risk factor for adverse outcomes after SARS-CoV-2 infection.


    Even a small increase in BMI above 23kg/m 2 is a risk factor for adverse outcomes after SARS-CoV-2 infection.


    In summary, the findings in this large population cohort study emphasize that being overweight is associated with a significant increase in the risk of severe COVID-19 outcomes, and it is also one of the most important modifiable risk factors discovered so far.


    And in the long run, these efforts to achieve a healthy weight can also help reduce the risk of type 2 diabetes, cardiovascular disease, and some cancers, which have persisted during the pandemic and put a continuous burden on health.


    References: Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study Min Gao, MSc * Carmen Piernas, PhD * Nerys M Astbury, PhD Prof Julia Hippisley -Cox, FRCP Prof Stephen O'Rahilly, FRS Prof Paul Aveyard, FRCGP † et al.
    Show all authors Show footnotes DOI:https://doi.
    org/10.
    1016/S2213-8587(21)00089-9 DOI:https: //doi.
    org/10.
    1016/S2213-8587(21)00089-9 Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.